Waldemarus
SpringWorks Therapeutics (NASDAQ:SWTX), which is reportedly in takeover talks with Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY), has received FDA approval for the drug mirdametinib for the treatment of neurofibromatosis type 1.
The drug, also known as Gomekli, was approved for the treatment of adult